| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.675 | 0.002 | 0.675 | Aromatase inhibitor | 0.473 0.003 DBMET02826 0.101 0.021 DBMET02828 0.117 0.018 DBMET02829 0.067 0.037 DBMET02827 | ||
| 0.479 | 0.014 | 0.479 | Anticonvulsant | 0.352 0.029 DBMET02826 0.187 0.093 DBMET02829 | ||
| 0.386 | 0.005 | 0.386 | Hedgehog signaling inhibitor | 0.178 0.015 DBMET02826 0.137 0.029 DBMET02829 | ||
| 0.311 | 0.004 | 0.318 | MAP kinase kinase 5 inhibitor | 0.28 0.004 DBMET02826 0.318 0.003 DBMET02829 0.224 0.014 DBMET02825 0.191 0.045 DBMET02827 | DBMET02829 | |
| 0.27 | 0.013 | 0.381 | Cell wall synthesis inhibitor | 0.243 0.017 DBMET02826 0.236 0.019 DBMET02828 0.186 0.036 DBMET02829 0.259 0.014 DBMET02825 0.381 0.007 DBMET02827 | DBMET02827 | |
| 0.258 | 0.007 | 0.258 | Raf kinase B inhibitor | 0.093 0.024 DBMET02826 0.249 0.007 DBMET02829 | ||
| 0.255 | 0.012 | 0.255 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.11 0.045 DBMET02826 0.247 0.013 DBMET02829 | ||
| 0.261 | 0.019 | 0.261 | M18 aspartyl aminopeptidase inhibitor | 0.18 0.04 DBMET02826 | ||
| 0.247 | 0.009 | 0.247 | Raf kinase inhibitor | 0.095 0.035 DBMET02826 0.247 0.009 DBMET02829 | ||
| 0.223 | 0.004 | 0.223 | Lanosterol 14 alpha demethylase inhibitor | 0.173 0.006 DBMET02826 0.095 0.064 DBMET02828 | ||
| 0.209 | 0.008 | 0.209 | Cannabinoid receptor antagonist | 0.131 0.018 DBMET02826 | ||
| 0.233 | 0.047 | 0.278 | P-glycoprotein inhibitor | 0.186 0.074 DBMET02826 0.278 0.034 DBMET02829 0.18 0.079 DBMET02827 | DBMET02829 | |
| 0.188 | 0.01 | 0.295 | Protein kinase C delta inhibitor | 0.174 0.013 DBMET02826 0.295 0.004 DBMET02829 0.08 0.077 DBMET02825 0.095 0.056 DBMET02827 | DBMET02829 | |
| 0.338 | 0.165 | 0.499 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.425 0.08 DBMET02828 0.499 0.034 DBMET02829 | DBMET02829 | |
| 0.175 | 0.003 | 0.175 | Estrone sulfatase inhibitor | 0.145 0.004 DBMET02826 0.086 0.005 DBMET02829 0.043 0.008 DBMET02827 | ||
| 0.229 | 0.064 | 0.229 | ErbB-1 antagonist | 0.177 0.12 DBMET02826 0.209 0.08 DBMET02829 | ||
| 0.174 | 0.014 | 0.441 | Phosphodiesterase 4D inhibitor | 0.078 0.049 DBMET02826 0.176 0.014 DBMET02829 0.441 0.004 DBMET02827 | DBMET02827 | |
| 0.161 | 0.006 | 0.161 | Cannabinoid CB1 receptor antagonist | 0.07 0.035 DBMET02826 | ||
| 0.276 | 0.133 | 0.507 | GABA C receptor rho-3 antagonist | 0.507 0.024 DBMET02828 0.351 0.085 DBMET02829 | DBMET02828 | |
| 0.151 | 0.01 | 0.151 | Cannabinoid CB1 receptor agonist | 0.13 0.013 DBMET02826 0.052 0.05 DBMET02829 | ||
| 0.271 | 0.134 | 0.479 | Immunosuppressant | 0.305 0.112 DBMET02826 0.461 0.044 DBMET02829 0.396 0.064 DBMET02825 0.479 0.039 DBMET02827 | DBMET02827 | |
| 0.143 | 0.008 | 0.143 | Cannabinoid CB2 receptor antagonist | 0.109 0.013 DBMET02826 | ||
| 0.169 | 0.035 | 0.205 | Sphingosine 1-phosphate receptor 5 antagonist | 0.163 0.042 DBMET02826 0.205 0.009 DBMET02829 | DBMET02829 | |
| 0.136 | 0.005 | 0.482 | Protein kinase C theta inhibitor | 0.482 0.002 DBMET02826 0.188 0.004 DBMET02829 0.178 0.004 DBMET02827 | DBMET02826 | |
| 0.148 | 0.023 | 0.148 | Phosphodiesterase IV inhibitor | 0.088 0.054 DBMET02829 | ||
| 0.121 | 0.005 | 0.121 | Exportin-1 inhibitor | 0.078 0.028 DBMET02826 0.096 0.011 DBMET02828 0.067 0.051 DBMET02829 | ||
| 0.153 | 0.037 | 0.185 | Sphingosine 1-phosphate receptor 2 antagonist | 0.14 0.055 DBMET02826 0.185 0.013 DBMET02829 | DBMET02829 | |
| 0.122 | 0.015 | 0.122 | Phosphatidylinositol 3-kinase delta inhibitor | |||
| 0.106 | 0.014 | 0.29 | Phosphodiesterase 4A inhibitor | 0.082 0.02 DBMET02829 0.29 0.005 DBMET02827 | DBMET02827 | |
| 0.108 | 0.019 | 0.747 | Protein kinase C alpha inhibitor | 0.747 0.002 DBMET02826 0.232 0.005 DBMET02829 0.364 0.003 DBMET02827 | DBMET02826 | |
| 0.104 | 0.019 | 0.104 | Sphingosine 1-phosphate receptor antagonist | 0.085 0.037 DBMET02826 0.077 0.052 DBMET02829 | ||
| 0.132 | 0.053 | 0.166 | Sphingosine 1-phosphate receptor 4 antagonist | 0.119 0.074 DBMET02826 0.166 0.021 DBMET02829 | DBMET02829 | |
| 0.085 | 0.006 | 0.085 | CC chemokine 4 receptor antagonist | 0.055 0.021 DBMET02826 0.056 0.02 DBMET02828 | ||
| 0.098 | 0.027 | 0.195 | Vanilloid 1 antagonist | 0.195 0.01 DBMET02829 | DBMET02829 | |
| 0.071 | 0.007 | 0.071 | Dopamine beta hydroxylase inhibitor | 0.048 0.035 DBMET02826 0.058 0.018 DBMET02828 0.057 0.019 DBMET02829 | ||
| 0.067 | 0.005 | 0.067 | Heme oxygenase inhibitor | 0.05 0.013 DBMET02826 0.05 0.013 DBMET02828 | ||
| 0.071 | 0.01 | 0.071 | CDK7/cyclin H inhibitor | 0.053 0.021 DBMET02826 | ||
| 0.116 | 0.056 | 0.116 | Granulocyte macrophage colony stimulating factor antagonist | |||
| 0.075 | 0.016 | 0.075 | Sphingosine 1-phosphate receptor 1 antagonist | 0.064 0.024 DBMET02826 | ||
| 0.195 | 0.137 | 0.202 | MAP kinase kinase 3 inhibitor | 0.192 0.148 DBMET02828 0.202 0.118 DBMET02829 | DBMET02829 | |
| 0.084 | 0.026 | 0.084 | Phosphatidylinositol kinase inhibitor | |||
| 0.114 | 0.058 | 0.525 | Ferrochelatase inhibitor | 0.193 0.024 DBMET02828 0.525 0.002 DBMET02829 | DBMET02829 | |
| 0.077 | 0.022 | 0.13 | Phosphodiesterase 4C inhibitor | 0.13 0.009 DBMET02829 | DBMET02829 | |
| 0.146 | 0.091 | 0.146 | Heat shock protein 90 alpha antagonist | |||
| 0.284 | 0.23 | 0.673 | Antiinflammatory | 0.292 0.223 DBMET02826 0.612 0.05 DBMET02829 0.518 0.08 DBMET02825 0.673 0.036 DBMET02827 | DBMET02827 | |
| 0.061 | 0.008 | 0.061 | 5 Hydroxytryptamine 1D agonist | |||
| 0.083 | 0.034 | 0.083 | Phosphodiesterase 4B inhibitor | 0.067 0.047 DBMET02829 | ||
| 0.133 | 0.091 | 0.133 | Pregnane X receptor agonist | 0.125 0.115 DBMET02829 | ||
| 0.063 | 0.024 | 0.063 | Thromboxane synthase inhibitor | 0.057 0.033 DBMET02826 0.057 0.033 DBMET02829 | ||
| 0.088 | 0.051 | 0.088 | GABA A receptor agonist | |||
| 0.107 | 0.069 | 0.107 | GABA receptor agonist | |||
| 0.081 | 0.047 | 0.081 | CYP2A6 inhibitor | 0.078 0.051 DBMET02828 | ||
| 0.046 | 0.014 | 0.046 | Plasma kallikrein inhibitor | |||
| 0.071 | 0.041 | 0.071 | Cannabinoid receptor agonist | 0.055 0.053 DBMET02826 | ||
| 0.081 | 0.051 | 0.081 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | |||
| 0.122 | 0.094 | 0.129 | Nav1.6 sodium channel blocker | 0.129 0.083 DBMET02828 0.12 0.096 DBMET02829 | DBMET02828 | |
| 0.033 | 0.011 | 0.033 | CC chemokine 1 receptor antagonist | |||
| 0.112 | 0.093 | 0.112 | Bone formation stimulant | 0.108 0.098 DBMET02826 | ||
| 0.125 | 0.105 | 0.125 | Heat shock protein 90 antagonist | |||
| 0.052 | 0.038 | 0.052 | 5 Hydroxytryptamine 1B agonist | |||
| 0.017 | 0.005 | 0.017 | Egl nine homolog 3 inhibitor | 0.014 0.006 DBMET02828 0.014 0.007 DBMET02829 | ||
| 0.027 | 0.017 | 0.028 | Thymidine phosphorylase inhibitor | 0.028 0.014 DBMET02828 | DBMET02828 | |
| 0.047 | 0.038 | 0.047 | Phosphatidylinositol 3-kinase beta inhibitor | |||
| 0.044 | 0.036 | 0.06 | Adenosine deaminase inhibitor | 0.05 0.031 DBMET02826 0.056 0.025 DBMET02828 0.06 0.021 DBMET02829 | DBMET02829 | |
| 0.136 | 0.128 | 0.221 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.221 0.066 DBMET02829 | DBMET02829 | |
| 0.029 | 0.022 | 0.029 | Glutamate (mGluR2) antagonist | |||
| 0.047 | 0.04 | 0.047 | Phosphatidylinositol 3-kinase alpha inhibitor | |||
| 0.022 | 0.016 | 0.075 | Bombesin agonist | 0.065 0.005 DBMET02828 0.075 0.005 DBMET02829 | DBMET02829 | |
| 0.052 | 0.048 | 0.052 | CDK9/cyclin T1 inhibitor | |||
| 0.018 | 0.014 | 0.067 | Bombesin 3 receptor agonist | 0.059 0.005 DBMET02828 0.067 0.004 DBMET02829 | DBMET02829 | |
| 0.035 | 0.031 | 0.059 | Glutamate (mGluR group II) antagonist | 0.059 0.011 DBMET02828 | DBMET02828 | |
| 0.085 | 0.082 | 0.193 | MAP kinase kinase kinase inhibitor | 0.193 0.02 DBMET02828 | DBMET02828 | |
| 0.048 | 0.046 | 0.048 | Dipeptidyl peptidase inhibitor | |||
| 0.025 | 0.023 | 0.06 | Protocollagen prolyl hydroxylase inhibitor | 0.06 0.005 DBMET02828 | DBMET02828 | |
| 0.047 | 0.044 | 0.047 | Alpha 1b adrenoreceptor agonist | |||
| 0.041 | 0.04 | 0.041 | Dipeptidyl peptidase IV inhibitor | |||
| 0.01 | 0.01 | 0.096 | Egl nine homolog 2 inhibitor | 0.096 0.002 DBMET02828 | DBMET02828 | |
| 0.032 | 0.037 | 0.075 | Alpha 1d adrenoreceptor agonist | 0.075 0.006 DBMET02828 | DBMET02828 | |
| 0.055 | 0.06 | 0.06 | Fibroblast growth factor 2 antagonist | 0.06 0.053 DBMET02828 | DBMET02828 | |
| 0.013 | 0.02 | 0.039 | Steroid 17-alpha-hydroxylase/17,20 lyase inhibitor | 0.039 0.007 DBMET02828 | DBMET02828 | |
| 0.078 | 0.09 | 0.178 | Creatine kinase inhibitor | 0.156 0.021 DBMET02828 0.178 0.015 DBMET02829 | DBMET02829 | |
| 0.174 | 0.187 | 0.259 | Hypoxia-inducible factor 1 alpha inhibitor | 0.259 0.092 DBMET02829 0.195 0.158 DBMET02825 | DBMET02829 | |
| 0.062 | 0.078 | 0.068 | Phosphodiesterase VIII inhibitor | 0.068 0.06 DBMET02828 | DBMET02828 | |
| 0.033 | 0.052 | 0.041 | Geranyltranstransferase inhibitor | 0.04 0.037 DBMET02828 0.041 0.034 DBMET02829 | DBMET02829 | |
| 0.021 | 0.046 | 0.029 | Estrogen-related receptor alpha antagonist | 0.029 0.027 DBMET02829 | DBMET02829 | |
| 0.059 | 0.084 | 0.077 | Leucine-rich repeat kinase 2 inhibitor | 0.077 0.06 DBMET02828 | DBMET02828 | |
| 0.026 | 0.052 | 0.031 | Vanilloid 4 antagonist | 0.031 0.027 DBMET02829 | DBMET02829 | |
| 0.031 | 0.058 | 0.04 | Sphingosine 1-phosphate receptor agonist | 0.04 0.037 DBMET02829 | DBMET02829 | |
| 0.087 | 0.114 | 0.312 | Cyclin-dependent kinase 7 inhibitor | 0.312 0.01 DBMET02828 | DBMET02828 | |
| 0.033 | 0.064 | 0.041 | Guanylate cyclase stimulant | 0.041 0.035 DBMET02829 | DBMET02829 | |
| 0.058 | 0.091 | 0.095 | MDM2 inhibitor | 0.095 0.009 DBMET02829 | DBMET02829 | |
| 0.082 | 0.115 | 0.177 | Cholesterol synthesis inhibitor | 0.177 0.033 DBMET02829 | DBMET02829 | |
| 0.021 | 0.055 | 0.069 | MAP3K8 inhibitor | 0.069 0.004 DBMET02828 | DBMET02828 | |
| 0.128 | 0.162 | 0.734 | Aldehyde oxidase inhibitor | 0.167 0.125 DBMET02826 0.324 0.06 DBMET02828 0.734 0.006 DBMET02829 | DBMET02829 | |
| 0.007 | 0.04 | 0.016 | Egl nine homolog 1 inhibitor | 0.016 0.008 DBMET02829 | DBMET02829 | |
| 0.173 | 0.209 | 0.384 | Vasodilator, coronary | 0.212 0.171 DBMET02828 0.384 0.041 DBMET02829 0.32 0.073 DBMET02825 0.373 0.045 DBMET02827 | DBMET02829 | |
| 0.059 | 0.095 | 0.098 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.098 0.015 DBMET02828 | DBMET02828 | |
| 0.071 | 0.107 | 0.12 | Estrogen-related receptor beta agonist | 0.082 0.059 DBMET02828 0.12 0.01 DBMET02829 | DBMET02829 | |
| 0.071 | 0.109 | 0.078 | CC chemokine 5 receptor agonist | 0.078 0.07 DBMET02828 | DBMET02828 | |
| 0.028 | 0.066 | 0.083 | AMPA 4 receptor antagonist | 0.083 0.006 DBMET02829 | DBMET02829 | |
| 0.029 | 0.067 | 0.045 | Thymidine kinase inhibitor | 0.045 0.023 DBMET02828 | DBMET02828 | |
| 0.011 | 0.049 | 0.017 | CC chemokine 9 receptor antagonist | 0.017 0.011 DBMET02829 | DBMET02829 | |
| 0.046 | 0.084 | 0.091 | Pregnane X receptor antagonist | 0.056 0.043 DBMET02828 0.091 0.004 DBMET02829 | DBMET02829 | |
| 0.011 | 0.055 | 0.022 | Integrin alphaVbeta1 antagonist | 0.022 0.01 DBMET02829 | DBMET02829 | |
| 0.066 | 0.114 | 0.241 | NADH dehydrogenase inhibitor | 0.111 0.034 DBMET02828 0.241 0.008 DBMET02829 0.106 0.038 DBMET02825 0.129 0.024 DBMET02827 | DBMET02829 | |
| 0.029 | 0.079 | 0.213 | Dihydroorotate dehydrogenase inhibitor | 0.213 0.004 DBMET02829 | DBMET02829 | |
| 0.076 | 0.126 | 0.213 | GABA C receptor antagonist | 0.183 0.017 DBMET02828 0.213 0.01 DBMET02829 | DBMET02829 | |
| 0.045 | 0.097 | 0.057 | Phosphodiesterase 1A inhibitor | 0.057 0.049 DBMET02828 | DBMET02828 | |
| 0.022 | 0.075 | 0.112 | Glutamate (mGluR3) antagonist | 0.112 0.004 DBMET02828 0.047 0.014 DBMET02829 | DBMET02828 | |
| 0.084 | 0.145 | 0.2 | Cathepsin H inhibitor | 0.145 0.05 DBMET02828 0.2 0.022 DBMET02829 | DBMET02829 | |
| 0.028 | 0.093 | 0.181 | Acyl-CoA dehydrogenase inhibitor | 0.068 0.028 DBMET02828 0.181 0.006 DBMET02829 | DBMET02829 | |
| 0.012 | 0.079 | 0.022 | Methylmalonyl-CoA mutase inhibitor | 0.022 0.006 DBMET02829 | DBMET02829 | |
| 0.029 | 0.098 | 0.067 | Glutamate (mGluR4) antagonist | 0.067 0.011 DBMET02829 | DBMET02829 | |
| 0.073 | 0.143 | 0.239 | Adenylate kinase inhibitor | 0.153 0.025 DBMET02828 0.239 0.011 DBMET02829 | DBMET02829 | |
| 0.023 | 0.093 | 0.053 | Histamine H2 receptor agonist | 0.053 0.019 DBMET02828 | DBMET02828 | |
| 0.026 | 0.096 | 0.055 | Mineralocorticoid receptor antagonist | 0.055 0.024 DBMET02829 | DBMET02829 | |
| 0.1 | 0.172 | 0.128 | LIM domain kinase 1 inhibitor | 0.128 0.123 DBMET02829 | DBMET02829 | |
| 0.012 | 0.084 | 0.078 | Retinoid X beta receptor antagonist | 0.078 0.002 DBMET02829 | DBMET02829 | |
| 0.079 | 0.153 | 0.117 | Estrogen antagonist | 0.117 0.06 DBMET02829 | DBMET02829 | |
| 0.11 | 0.184 | 0.163 | CC chemokine 6 receptor antagonist | 0.163 0.01 DBMET02829 0.14 0.039 DBMET02825 0.137 0.046 DBMET02827 | DBMET02829 | |
| 0.015 | 0.092 | 0.051 | Retinoid X gamma receptor antagonist | 0.051 0.003 DBMET02829 | DBMET02829 | |
| 0.061 | 0.14 | 0.36 | GABA C receptor agonist | 0.283 0.01 DBMET02828 0.36 0.006 DBMET02829 | DBMET02829 | |
| 0.05 | 0.129 | 0.06 | Calcium channel P-type blocker | 0.06 0.058 DBMET02829 | DBMET02829 | |
| 0.13 | 0.212 | 0.207 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.184 0.088 DBMET02828 0.207 0.066 DBMET02829 | DBMET02829 | |
| 0.059 | 0.142 | 0.119 | Protein kinase (CK2) alpha inhibitor | 0.098 0.078 DBMET02828 0.119 0.063 DBMET02829 | DBMET02829 | |
| 0.008 | 0.093 | 0.195 | Retinoid X beta receptor agonist | 0.195 0.003 DBMET02829 | DBMET02829 | |
| 0.036 | 0.125 | 0.499 | Porphobilinogen synthase inhibitor | 0.167 0.017 DBMET02828 0.499 0.003 DBMET02829 | DBMET02829 | |
| 0.014 | 0.103 | 0.066 | Cholesterol ester transfer protein antagonist | 0.066 0.004 DBMET02829 | DBMET02829 | |
| 0.034 | 0.126 | 0.052 | Vanilloid 2 antagonist | 0.052 0.037 DBMET02829 | DBMET02829 | |
| 0.017 | 0.115 | 0.063 | Guanylate cyclase inhibitor | 0.063 0.009 DBMET02829 | DBMET02829 | |
| 0.017 | 0.115 | 0.044 | AMPA receptor antagonist | 0.044 0.037 DBMET02829 | DBMET02829 | |
| 0.026 | 0.124 | 0.047 | Cathepsin F inhibitor | 0.047 0.018 DBMET02829 | DBMET02829 | |
| 0.023 | 0.122 | 0.035 | Potassium channel Kv1.1 blocker | 0.035 0.033 DBMET02829 | DBMET02829 | |
| 0.042 | 0.141 | 0.058 | Phosphodiesterase 1C inhibitor | 0.058 0.053 DBMET02828 | DBMET02828 | |
| 0.005 | 0.106 | 0.038 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.038 0.013 DBMET02828 | DBMET02828 | |
| 0.043 | 0.143 | 0.22 | Potassium channel (Ca-activated) activator | 0.116 0.044 DBMET02828 0.22 0.011 DBMET02829 | DBMET02829 | |
| 0.013 | 0.116 | 0.039 | Vascular adhesion protein 1 inhibitor | 0.039 0.027 DBMET02828 | DBMET02828 | |
| 0.12 | 0.223 | 0.384 | Cardiotonic | 0.384 0.032 DBMET02829 | DBMET02829 | |
| 0.142 | 0.248 | 0.232 | Neuropeptide Y2 antagonist | 0.232 0.074 DBMET02829 | DBMET02829 | |
| 0.094 | 0.206 | 0.196 | Melanin inhibitor | 0.196 0.043 DBMET02829 | DBMET02829 | |
| 0.016 | 0.129 | 0.05 | Angiotensin AT1 receptor antagonist | 0.05 0.018 DBMET02828 0.042 0.03 DBMET02829 | DBMET02828 | |
| 0.06 | 0.173 | 0.149 | MAP kinase kinase 1 inhibitor | 0.149 0.017 DBMET02829 | DBMET02829 | |
| 0.011 | 0.125 | 0.077 | Fumarate hydratase inhibitor | 0.032 0.026 DBMET02828 0.077 0.007 DBMET02829 | DBMET02829 | |
| 0.041 | 0.156 | 0.243 | Glutamate dehydrogenase inhibitor | 0.084 0.041 DBMET02828 0.243 0.007 DBMET02829 | DBMET02829 | |
| 0.007 | 0.123 | 0.131 | Retinoid X gamma receptor agonist | 0.131 0.003 DBMET02829 | DBMET02829 | |
| 0.114 | 0.231 | 0.181 | Ca2+-transporting ATPase inhibitor | 0.155 0.031 DBMET02828 0.181 0.006 DBMET02829 | DBMET02829 | |
| 0.022 | 0.139 | 0.564 | Alcohol oxidase inhibitor | 0.13 0.013 DBMET02828 0.564 0.003 DBMET02829 | DBMET02829 | |
| 0.011 | 0.132 | 0.075 | Urate transporter 1 inhibitor | 0.075 0.009 DBMET02828 0.058 0.015 DBMET02829 | DBMET02828 | |
| 0.026 | 0.147 | 0.085 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.085 0.018 DBMET02828 0.053 0.043 DBMET02829 | DBMET02828 | |
| 0.033 | 0.154 | 0.127 | Purinergic P2X1 antagonist | 0.127 0.01 DBMET02829 | DBMET02829 | |
| 0.063 | 0.186 | 0.653 | Alpha-N-acetylglucosaminidase inhibitor | 0.292 0.017 DBMET02828 0.653 0.003 DBMET02829 0.118 0.079 DBMET02825 0.113 0.085 DBMET02827 | DBMET02829 | |
| 0.122 | 0.244 | 0.332 | Lipoxygenase inhibitor | 0.332 0.057 DBMET02829 | DBMET02829 | |
| 0.013 | 0.136 | 0.076 | Purinergic P2Y antagonist | 0.076 0.014 DBMET02829 | DBMET02829 | |
| 0.009 | 0.132 | 0.027 | Nicotinic alpha3beta4 receptor agonist | 0.027 0.026 DBMET02828 | DBMET02828 | |
| 0.089 | 0.214 | 0.197 | GABA C receptor rho-2 antagonist | 0.197 0.03 DBMET02828 0.152 0.07 DBMET02829 | DBMET02828 | |
| 0.067 | 0.192 | 0.254 | TRPA1 agonist | 0.254 0.005 DBMET02829 | DBMET02829 | |
| 0.015 | 0.141 | 0.036 | Angiotensin II receptor antagonist | 0.036 0.02 DBMET02828 | DBMET02828 | |
| 0.15 | 0.277 | 0.349 | Toll-Like receptor 7 agonist | 0.349 0.082 DBMET02829 | DBMET02829 | |
| 0.018 | 0.147 | 0.049 | Glutamate (mGluR1a) antagonist | 0.049 0.021 DBMET02829 | DBMET02829 | |
| 0.023 | 0.154 | 0.042 | Vanilloid 3 antagonist | 0.042 0.018 DBMET02829 | DBMET02829 | |
| 0.008 | 0.139 | 0.035 | Sodium/glucose cotransporter 2 inhibitor | 0.035 0.01 DBMET02827 | DBMET02827 | |
| 0.053 | 0.185 | 0.134 | Bile acid receptor antagonist | 0.134 0.011 DBMET02829 | DBMET02829 | |
| 0.14 | 0.272 | 0.22 | 5 Hydroxytryptamine 3E antagonist | 0.22 0.036 DBMET02828 | DBMET02828 | |
| 0.031 | 0.164 | 0.133 | Dihydroorotate oxidase inhibitor | 0.061 0.028 DBMET02828 0.133 0.003 DBMET02829 | DBMET02829 | |
| 0.132 | 0.267 | 0.459 | Angiogenesis inhibitor | 0.459 0.038 DBMET02828 | DBMET02828 | |
| 0.023 | 0.158 | 0.097 | Carbamoyl phosphate synthetase inhibitor | 0.097 0.021 DBMET02828 0.071 0.034 DBMET02829 | DBMET02828 | |
| 0.044 | 0.179 | 0.119 | Potassium channel activator | 0.119 0.033 DBMET02829 | DBMET02829 | |
| 0.025 | 0.161 | 0.06 | Glutamate (mGluR group III) antagonist | 0.051 0.02 DBMET02828 0.06 0.013 DBMET02829 | DBMET02829 | |
| 0.038 | 0.174 | 0.247 | Ornithine decarboxylase inhibitor | 0.247 0.004 DBMET02829 | DBMET02829 | |
| 0.009 | 0.149 | 0.035 | Phosphoglycerate kinase inhibitor | 0.035 0.024 DBMET02829 | DBMET02829 | |
| 0.067 | 0.208 | 0.149 | Calcium channel blocker | 0.149 0.059 DBMET02829 | DBMET02829 | |
| 0.018 | 0.159 | 0.036 | MAP3K5 inhibitor | 0.036 0.033 DBMET02828 | DBMET02828 | |
| 0.007 | 0.148 | 0.027 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.027 0.02 DBMET02829 | DBMET02829 | |
| 0.011 | 0.153 | 0.058 | Cathepsin L2 inhibitor | 0.058 0.019 DBMET02829 | DBMET02829 | |
| 0.004 | 0.146 | 0.029 | 5-Alpha-reductase 1 inhibitor | 0.029 0.009 DBMET02829 | DBMET02829 | |
| 0.003 | 0.146 | 0.011 | Thrombopoietin agonist | 0.011 0.009 DBMET02829 | DBMET02829 | |
| 0.047 | 0.19 | 0.24 | Uric acid excretion stimulant | 0.24 0.008 DBMET02829 0.091 0.064 DBMET02825 0.102 0.05 DBMET02827 | DBMET02829 | |
| 0.017 | 0.161 | 0.076 | Retinoid X alpha receptor antagonist | 0.076 0.003 DBMET02829 | DBMET02829 | |
| 0.01 | 0.154 | 0.032 | Sodium/glucose cotransporter inhibitor | 0.032 0.01 DBMET02827 | DBMET02827 | |
| 0.003 | 0.149 | 0.019 | Carbonic anhydrase X inhibitor | 0.017 0.012 DBMET02828 0.019 0.009 DBMET02829 | DBMET02829 | |
| 0.003 | 0.149 | 0.019 | Carbonic anhydrase VIII inhibitor | 0.017 0.012 DBMET02828 0.019 0.009 DBMET02829 | DBMET02829 | |
| 0.022 | 0.167 | 0.213 | Biliverdin reductase inhibitor | 0.077 0.028 DBMET02828 0.213 0.005 DBMET02829 | DBMET02829 | |
| 0.076 | 0.222 | 0.205 | Arachidonic acid antagonist | 0.178 0.056 DBMET02828 0.205 0.029 DBMET02829 | DBMET02829 | |
| 0.008 | 0.156 | 0.036 | Prostaglandin EP4 antagonist | 0.036 0.012 DBMET02829 | DBMET02829 | |
| 0.032 | 0.183 | 0.151 | Calcium antagonist | 0.151 0.022 DBMET02829 | DBMET02829 | |
| 0.018 | 0.17 | 0.086 | Retinoid X receptor antagonist | 0.086 0.003 DBMET02829 | DBMET02829 | |
| 0.048 | 0.201 | 0.146 | Anabolic | 0.1 0.062 DBMET02828 0.146 0.02 DBMET02829 | DBMET02829 | |
| 0.002 | 0.156 | 0.013 | Glutamate (mGluR6) agonist | 0.013 0.008 DBMET02829 | DBMET02829 | |
| 0.021 | 0.175 | 0.157 | Phosphofructokinase-1 inhibitor | 0.095 0.034 DBMET02828 0.157 0.017 DBMET02829 0.06 0.056 DBMET02827 | DBMET02829 | |
| 0.02 | 0.176 | 0.086 | Diacylglycerol O-acyltransferase inhibitor | 0.086 0.011 DBMET02829 | DBMET02829 | |
| 0.104 | 0.261 | 0.186 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.186 0.087 DBMET02828 | DBMET02828 | |
| 0.022 | 0.18 | 0.045 | GABA B receptor antagonist | 0.045 0.027 DBMET02829 | DBMET02829 | |
| 0.113 | 0.271 | 0.658 | MAP-kinase-activated kinase 5 inhibitor | 0.658 0.003 DBMET02828 | DBMET02828 | |
| 0.139 | 0.297 | 0.339 | Toll-Like receptor agonist | 0.339 0.088 DBMET02829 | DBMET02829 | |
| 0.025 | 0.185 | 0.064 | Squalene epoxidase inhibitor | 0.064 0.018 DBMET02829 | DBMET02829 | |
| 0.083 | 0.244 | 0.15 | Adenylate cyclase stimulant | 0.133 0.094 DBMET02828 0.15 0.062 DBMET02829 | DBMET02829 | |
| 0.016 | 0.18 | 0.057 | Thromboxane antagonist | 0.057 0.035 DBMET02829 | DBMET02829 | |
| 0.094 | 0.258 | 0.312 | Succinate dehydrogenase inhibitor | 0.218 0.037 DBMET02828 0.312 0.009 DBMET02829 | DBMET02829 | |
| 0.109 | 0.273 | 0.523 | Superoxide dismutase inhibitor | 0.243 0.079 DBMET02828 0.523 0.011 DBMET02829 | DBMET02829 | |
| 0.06 | 0.225 | 0.305 | Aldehyde dehydrogenase inhibitor | 0.305 0.011 DBMET02829 | DBMET02829 | |
| 0.01 | 0.176 | 0.025 | Lysophosphatidic acid receptor 1 agonist | 0.025 0.017 DBMET02829 | DBMET02829 | |
| 0.062 | 0.228 | 0.103 | Acetylcholine release stimulant | 0.103 0.081 DBMET02829 | DBMET02829 | |
| 0.059 | 0.225 | 0.147 | Glutamate release inhibitor | 0.147 0.01 DBMET02829 | DBMET02829 | |
| 0.118 | 0.285 | 0.631 | Cholesterol antagonist | 0.631 0.015 DBMET02829 0.287 0.099 DBMET02825 0.472 0.037 DBMET02827 | DBMET02829 | |
| 0.004 | 0.17 | 0.036 | Prostaglandin H2 antagonist | 0.036 0.008 DBMET02829 | DBMET02829 | |
| 0.022 | 0.19 | 0.082 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.082 0.015 DBMET02829 | DBMET02829 | |
| 0.039 | 0.207 | 0.183 | Glycine receptor agonist | 0.07 0.054 DBMET02828 0.183 0.005 DBMET02829 | DBMET02829 | |
| 0.011 | 0.18 | 0.029 | Purinergic P2Y15 antagonist | 0.029 0.019 DBMET02828 | DBMET02828 | |
| 0.048 | 0.22 | 0.142 | GABA C receptor rho-1 antagonist | 0.142 0.025 DBMET02828 0.142 0.025 DBMET02829 | DBMET02829 | |
| 0.13 | 0.301 | 0.276 | 15-Lipoxygenase inhibitor | 0.276 0.146 DBMET02828 | DBMET02828 | |
| 0.021 | 0.194 | 0.203 | Aconitate hydratase inhibitor | 0.069 0.019 DBMET02828 0.203 0.003 DBMET02829 | DBMET02829 | |
| 0.022 | 0.196 | 0.056 | Aldosterone antagonist | 0.056 0.023 DBMET02829 | DBMET02829 | |
| 0.009 | 0.184 | 0.144 | Retinoid X alpha receptor agonist | 0.144 0.003 DBMET02829 | DBMET02829 | |
| 0.034 | 0.21 | 0.137 | Adenine nucleotide translocase inhibitor | 0.137 0.003 DBMET02829 0.063 0.024 DBMET02825 0.069 0.016 DBMET02827 | DBMET02829 | |
| 0.051 | 0.228 | 0.099 | Calcium channel (voltage-sensitive) blocker | 0.099 0.086 DBMET02829 | DBMET02829 | |
| 0.04 | 0.218 | 0.114 | Bronchodilator | 0.114 0.049 DBMET02826 | DBMET02826 | |
| 0.118 | 0.297 | 0.245 | RNA-directed DNA polymerase inhibitor | 0.207 0.089 DBMET02828 0.245 0.052 DBMET02829 | DBMET02829 | |
| 0.037 | 0.22 | 0.115 | Peroxisome proliferator-activated receptor gamma antagonist | 0.115 0.01 DBMET02829 | DBMET02829 | |
| 0.022 | 0.205 | 0.061 | Glucose-6-phosphate isomerase inhibitor | 0.061 0.018 DBMET02828 0.056 0.022 DBMET02829 | DBMET02828 | |
| 0.061 | 0.245 | 0.442 | Peroxidase inhibitor | 0.442 0.015 DBMET02828 0.311 0.035 DBMET02829 | DBMET02828 | |
| 0.046 | 0.23 | 0.23 | Xanthine oxidase inhibitor | 0.23 0.014 DBMET02828 0.175 0.026 DBMET02829 | DBMET02828 | |
| 0.042 | 0.226 | 0.319 | UDP-glucose 4-epimerase inhibitor | 0.146 0.03 DBMET02828 0.319 0.009 DBMET02829 0.1 0.061 DBMET02825 0.099 0.062 DBMET02827 | DBMET02829 | |
| 0.084 | 0.27 | 0.161 | CF transmembrane conductance regulator agonist | 0.161 0.058 DBMET02828 0.161 0.059 DBMET02829 | DBMET02829 | |
| 0.022 | 0.21 | 0.072 | Carbonic anhydrase stimulant | 0.072 0.03 DBMET02828 | DBMET02828 | |
| 0.047 | 0.236 | 0.151 | MAP kinase kinase inhibitor | 0.151 0.051 DBMET02829 | DBMET02829 | |
| 0.083 | 0.272 | 0.243 | Interferon gamma antagonist | 0.243 0.03 DBMET02829 0.13 0.111 DBMET02825 0.152 0.075 DBMET02827 | DBMET02829 | |
| 0.07 | 0.26 | 0.183 | Cyclin-dependent kinase 8 inhibitor | 0.183 0.049 DBMET02828 | DBMET02828 | |
| 0.035 | 0.226 | 0.114 | Falcipain 3 inhibitor | 0.114 0.058 DBMET02828 | DBMET02828 | |
| 0.044 | 0.235 | 0.376 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.098 0.056 DBMET02828 0.376 0.004 DBMET02829 | DBMET02829 | |
| 0.015 | 0.207 | 0.115 | Dihydroorotase inhibitor | 0.115 0.005 DBMET02829 | DBMET02829 | |
| 0.031 | 0.223 | 0.12 | Calcium channel L-type blocker | 0.12 0.016 DBMET02829 | DBMET02829 | |
| 0.047 | 0.241 | 0.088 | mTOR complex 2 inhibitor | 0.088 0.05 DBMET02828 | DBMET02828 | |
| 0.01 | 0.205 | 0.082 | Ornithine carbamoyltransferase inhibitor | 0.051 0.039 DBMET02828 0.082 0.021 DBMET02829 | DBMET02829 | |
| 0.045 | 0.241 | 0.153 | AMP-activated protein kinase stimulant | 0.153 0.026 DBMET02829 0.115 0.054 DBMET02827 | DBMET02829 | |
| 0.001 | 0.198 | 0.008 | Integrin alpha5beta6 antagonist | 0.008 0.004 DBMET02828 | DBMET02828 | |
| 0.009 | 0.206 | 0.031 | Vanilloid 2 agonist | 0.031 0.009 DBMET02829 | DBMET02829 | |
| 0.035 | 0.233 | 0.055 | Immunoglobulin Fc receptor antagonist | 0.055 0.038 DBMET02829 | DBMET02829 | |
| 0.016 | 0.214 | 0.144 | Argininosuccinate synthase inhibitor | 0.064 0.034 DBMET02828 0.144 0.012 DBMET02829 | DBMET02829 | |
| 0.007 | 0.205 | 0.037 | 5-Alpha-reductase 2 inhibitor | 0.037 0.008 DBMET02829 | DBMET02829 | |
| 0.027 | 0.226 | 0.059 | Potassium channel intermediate-conductance Ca-activated blocker | 0.059 0.043 DBMET02829 | DBMET02829 | |
| 0.029 | 0.23 | 0.067 | Aryl hydrocarbon receptor antagonist | 0.067 0.042 DBMET02828 | DBMET02828 | |
| 0.011 | 0.214 | 0.044 | Potassium channel Kv1.3 blocker | 0.044 0.036 DBMET02829 | DBMET02829 | |
| 0.014 | 0.217 | 0.047 | Glutamate (mGluR3) agonist | 0.044 0.007 DBMET02828 0.047 0.006 DBMET02829 | DBMET02829 | |
| 0.026 | 0.229 | 0.093 | Protein kinase (CK2) inhibitor | 0.088 0.074 DBMET02828 0.093 0.07 DBMET02829 | DBMET02829 | |
| 0.014 | 0.217 | 0.058 | Membrane dipeptidase inhibitor | 0.058 0.011 DBMET02829 | DBMET02829 | |
| 0.031 | 0.235 | 0.158 | Alcohol dehydrogenase inhibitor | 0.126 0.031 DBMET02828 0.158 0.018 DBMET02829 | DBMET02829 | |
| 0.041 | 0.245 | 0.081 | Estrogen receptor alpha antagonist | 0.081 0.047 DBMET02829 | DBMET02829 | |
| 0.022 | 0.227 | 0.073 | Na+ K+ transporting ATPase inhibitor | 0.073 0.057 DBMET02828 | DBMET02828 | |
| 0.006 | 0.212 | 0.123 | Retinoid X receptor agonist | 0.123 0.003 DBMET02829 | DBMET02829 | |
| 0.011 | 0.218 | 0.056 | Thromboxane A2 antagonist | 0.056 0.031 DBMET02829 | DBMET02829 | |
| 0.004 | 0.212 | 0.049 | Prostaglandin EP2 agonist | 0.049 0.006 DBMET02829 | DBMET02829 | |
| 0.019 | 0.234 | 0.08 | Leukotriene B4 antagonist | 0.08 0.015 DBMET02829 | DBMET02829 | |
| 0.077 | 0.294 | 0.3 | Tumour necrosis factor alpha release inhibitor | 0.262 0.069 DBMET02829 0.236 0.081 DBMET02825 0.3 0.053 DBMET02827 | DBMET02827 | |
| 0.014 | 0.233 | 0.026 | Hedgehog signaling activator | 0.026 0.024 DBMET02828 | DBMET02828 | |
| 0.004 | 0.225 | 0.065 | Retinoic acid receptor gamma antagonist | 0.065 0.003 DBMET02829 | DBMET02829 | |
| 0.015 | 0.237 | 0.038 | Protein kinase (CK2) beta inhibitor | 0.038 0.015 DBMET02828 | DBMET02828 | |
| 0.021 | 0.244 | 0.206 | Glutamate decarboxylase inhibitor | 0.112 0.024 DBMET02828 0.206 0.006 DBMET02829 | DBMET02829 | |
| 0.005 | 0.228 | 0.077 | Retinoic acid receptor antagonist | 0.077 0.003 DBMET02829 | DBMET02829 | |
| 0.051 | 0.274 | 0.096 | Electron transport complex I inhibitor | 0.096 0.092 DBMET02829 | DBMET02829 | |
| 0.107 | 0.334 | 0.473 | Vasodilator, peripheral | 0.473 0.034 DBMET02829 | DBMET02829 | |
| 0.071 | 0.298 | 0.124 | DNA repair enzyme inhibitor | 0.115 0.082 DBMET02828 0.124 0.065 DBMET02827 | DBMET02827 | |
| 0.02 | 0.248 | 0.056 | Cyclin D1 inhibitor | 0.056 0.05 DBMET02828 | DBMET02828 | |
| 0.014 | 0.243 | 0.043 | Histamine H1 receptor agonist | 0.043 0.032 DBMET02828 | DBMET02828 | |
| 0.064 | 0.295 | 0.158 | I kappa B kinase epsilon inhibitor | 0.153 0.116 DBMET02828 0.158 0.111 DBMET02829 | DBMET02829 | |
| 0.061 | 0.292 | 0.229 | Mannose-6-phosphate isomerase inhibitor | 0.152 0.063 DBMET02828 0.229 0.018 DBMET02829 | DBMET02829 | |
| 0.029 | 0.262 | 0.221 | Glycogen synthase kinase-3 beta inhibitor | 0.221 0.024 DBMET02828 | DBMET02828 | |
| 0.035 | 0.27 | 0.238 | Cystathionine beta-synthase inhibitor | 0.115 0.062 DBMET02828 0.238 0.017 DBMET02829 | DBMET02829 | |
| 0.003 | 0.239 | 0.018 | Alpha 2a adrenoreceptor agonist | 0.018 0.012 DBMET02828 | DBMET02828 | |
| 0.016 | 0.253 | 0.058 | Glutamate (mGluR8) agonist | 0.039 0.024 DBMET02828 0.058 0.008 DBMET02829 | DBMET02829 | |
| 0.039 | 0.277 | 0.088 | GABA B receptor agonist | 0.088 0.028 DBMET02829 | DBMET02829 | |
| 0.008 | 0.248 | 0.054 | Retinoic acid gamma receptor agonist | 0.054 0.003 DBMET02829 | DBMET02829 | |
| 0.005 | 0.247 | 0.06 | 5-Alpha-reductase inhibitor | 0.06 0.016 DBMET02829 | DBMET02829 | |
| 0.012 | 0.253 | 0.113 | Xanthine dehydrogenase inhibitor | 0.113 0.012 DBMET02828 0.107 0.014 DBMET02829 | DBMET02828 | |
| 0.032 | 0.273 | 0.144 | Glycogen synthase kinase-3 alpha inhibitor | 0.144 0.07 DBMET02828 | DBMET02828 | |
| 0.003 | 0.245 | 0.07 | Retinoic acid beta receptor antagonist | 0.07 0.003 DBMET02829 | DBMET02829 | |
| 0.035 | 0.279 | 0.068 | Heme oxygenase stimulant | 0.068 0.028 DBMET02829 | DBMET02829 | |
| 0.015 | 0.262 | 0.073 | CDC7 inhibitor | 0.073 0.041 DBMET02828 | DBMET02828 | |
| 0.018 | 0.264 | 0.084 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.053 0.012 DBMET02828 0.084 0.004 DBMET02829 | DBMET02829 | |
| 0.018 | 0.265 | 0.215 | Histidine decarboxylase inhibitor | 0.081 0.042 DBMET02828 0.215 0.011 DBMET02829 | DBMET02829 | |
| 0.031 | 0.278 | 0.075 | Orexin receptor 1 antagonist | 0.075 0.043 DBMET02828 | DBMET02828 | |
| 0.147 | 0.396 | 0.266 | MAP kinase kinase 6 inhibitor | 0.266 0.171 DBMET02828 | DBMET02828 | |
| 0.041 | 0.291 | 0.079 | MAP kinase kinase 7 inhibitor | 0.079 0.048 DBMET02828 | DBMET02828 | |
| 0.018 | 0.268 | 0.059 | Kainate receptor agonist | 0.04 0.032 DBMET02828 0.059 0.008 DBMET02829 | DBMET02829 | |
| 0.02 | 0.271 | 0.131 | Nav1.8 sodium channel blocker | 0.131 0.017 DBMET02829 | DBMET02829 | |
| 0.026 | 0.278 | 0.078 | Macrophage migration inhibitory factor inhibitor | 0.078 0.054 DBMET02829 | DBMET02829 | |
| 0.045 | 0.297 | 0.119 | Microtubule formation inhibitor | 0.119 0.062 DBMET02829 | DBMET02829 | |
| 0.027 | 0.286 | 0.234 | Glycogen synthase kinase-3 inhibitor | 0.234 0.024 DBMET02828 | DBMET02828 | |
| 0.033 | 0.293 | 0.101 | Glutamate (mGluR6) antagonist | 0.073 0.034 DBMET02828 0.101 0.01 DBMET02829 | DBMET02829 | |
| 0.017 | 0.278 | 0.063 | Androgen agonist | 0.063 0.037 DBMET02829 | DBMET02829 | |
| 0.017 | 0.285 | 0.069 | Leukotriene synthesis inhibitor | 0.069 0.045 DBMET02829 | DBMET02829 | |
| 0.064 | 0.333 | 0.182 | Antipruritic | 0.182 0.062 DBMET02829 | DBMET02829 | |
| 0.045 | 0.315 | 0.167 | DOPA decarboxylase inhibitor | 0.115 0.051 DBMET02828 0.167 0.014 DBMET02829 | DBMET02829 | |
| 0.003 | 0.276 | 0.036 | Prostaglandin E2 agonist | 0.036 0.008 DBMET02829 | DBMET02829 | |
| 0.031 | 0.304 | 0.113 | Prolactin inhibitor | 0.113 0.043 DBMET02828 0.113 0.044 DBMET02829 | DBMET02829 | |
| 0.004 | 0.281 | 0.031 | Kynurenine 3 monooxygenase inhibitor | 0.031 0.014 DBMET02829 | DBMET02829 | |
| 0.049 | 0.326 | 0.365 | Anesthetic general | 0.365 0.021 DBMET02829 | DBMET02829 | |
| 0.047 | 0.324 | 0.144 | Protein kinase stimulant | 0.144 0.072 DBMET02829 | DBMET02829 | |
| 0.008 | 0.289 | 0.081 | Prostaglandin E2 antagonist | 0.081 0.019 DBMET02829 | DBMET02829 | |
| 0.02 | 0.302 | 0.119 | Aminopeptidase I inhibitor | 0.076 0.047 DBMET02828 0.119 0.02 DBMET02829 | DBMET02829 | |
| 0.016 | 0.299 | 0.058 | Sphingosine 1-phosphate receptor 4 agonist | 0.058 0.057 DBMET02829 | DBMET02829 | |
| 0.009 | 0.293 | 0.029 | Glutamate (mGluR1) agonist | 0.029 0.011 DBMET02829 | DBMET02829 | |
| 0.016 | 0.303 | 0.055 | Sphingosine 1-phosphate receptor 3 antagonist | 0.055 0.047 DBMET02829 | DBMET02829 | |
| 0.073 | 0.36 | 0.274 | Phospholipase C inhibitor | 0.274 0.021 DBMET02829 | DBMET02829 | |
| 0.007 | 0.296 | 0.04 | ATP citrate lysase inhibitor | 0.04 0.013 DBMET02829 | DBMET02829 | |
| 0.053 | 0.342 | 0.362 | Immunostimulant | 0.298 0.079 DBMET02829 0.316 0.074 DBMET02825 0.362 0.061 DBMET02827 | DBMET02827 | |
| 0.111 | 0.401 | 0.279 | Tyrosine 3 hydroxylase inhibitor | 0.279 0.045 DBMET02828 0.237 0.081 DBMET02829 | DBMET02828 | |
| 0.004 | 0.295 | 0.043 | Leukotriene B4 receptor 1 antagonist | 0.043 0.01 DBMET02829 | DBMET02829 | |
| 0.03 | 0.322 | 0.126 | Protein kinase C gamma inhibitor | 0.126 0.048 DBMET02828 | DBMET02828 | |
| 0.034 | 0.329 | 0.258 | Triose-phosphate isomerase inhibitor | 0.113 0.036 DBMET02828 0.258 0.006 DBMET02829 | DBMET02829 | |
| 0.035 | 0.33 | 0.123 | Thioredoxin inhibitor | 0.123 0.029 DBMET02825 | DBMET02825 | |
| 0.004 | 0.3 | 0.048 | Prostaglandin agonist | 0.048 0.011 DBMET02829 | DBMET02829 | |
| 0.021 | 0.318 | 0.061 | Orexin receptor antagonist | 0.061 0.057 DBMET02828 | DBMET02828 | |
| 0.006 | 0.304 | 0.028 | Neuraminidase (Influenza B) inhibitor | 0.028 0.005 DBMET02829 | DBMET02829 | |
| 0.015 | 0.315 | 0.133 | Protein kinase (CK1) delta inhibitor | 0.133 0.064 DBMET02828 | DBMET02828 | |
| 0.032 | 0.333 | 0.099 | Beta glucuronidase inhibitor | 0.097 0.074 DBMET02828 0.099 0.072 DBMET02827 | DBMET02827 | |
| 0.027 | 0.328 | 0.066 | Leukotriene C antagonist | 0.058 0.033 DBMET02828 0.066 0.019 DBMET02829 | DBMET02829 | |
| 0.018 | 0.321 | 0.043 | Leukotriene C4 antagonist | 0.043 0.018 DBMET02829 | DBMET02829 | |
| 0.014 | 0.319 | 0.109 | MAP kinase 10 inhibitor | 0.109 0.03 DBMET02828 | DBMET02828 | |
| 0.004 | 0.31 | 0.023 | Glutamate (mGluR1a) agonist | 0.023 0.014 DBMET02828 | DBMET02828 | |
| 0.105 | 0.412 | 0.221 | Nitric-oxide synthase stimulant | 0.221 0.059 DBMET02828 0.166 0.162 DBMET02829 | DBMET02828 | |
| 0.058 | 0.366 | 0.131 | Hemostatic | 0.131 0.095 DBMET02829 | DBMET02829 | |
| 0.051 | 0.36 | 0.166 | Thiol protease inhibitor | 0.166 0.057 DBMET02829 | DBMET02829 | |
| 0.034 | 0.342 | 0.121 | Src kinase inhibitor | 0.121 0.107 DBMET02828 | DBMET02828 | |
| 0.134 | 0.444 | 0.575 | 5 Hydroxytryptamine release inhibitor | 0.575 0.015 DBMET02828 0.439 0.056 DBMET02829 | DBMET02828 | |
| 0.047 | 0.359 | 0.162 | Farnesoid X receptor antagonist | 0.162 0.04 DBMET02829 | DBMET02829 | |
| 0.005 | 0.317 | 0.028 | Diacylglycerol O-acyltransferase 1 inhibitor | 0.028 0.021 DBMET02829 | DBMET02829 | |
| 0.013 | 0.326 | 0.056 | Alpha-mannosidase inhibitor | 0.056 0.033 DBMET02828 0.054 0.035 DBMET02829 | DBMET02828 | |
| 0.011 | 0.33 | 0.065 | Lysophosphatidic acid 3 receptor antagonist | 0.065 0.018 DBMET02829 | DBMET02829 | |
| 0.011 | 0.33 | 0.081 | Leukotriene antagonist | 0.081 0.031 DBMET02829 | DBMET02829 | |
| 0.013 | 0.333 | 0.041 | AICAR transformylase inhibitor | 0.041 0.036 DBMET02829 | DBMET02829 | |
| 0.014 | 0.335 | 0.107 | Neuraminidase (influenza) inhibitor | 0.107 0.014 DBMET02829 0.067 0.039 DBMET02827 | DBMET02829 | |
| 0.117 | 0.44 | 0.336 | 5 Hydroxytryptamine uptake stimulant | 0.263 0.069 DBMET02828 0.336 0.03 DBMET02829 | DBMET02829 | |
| 0.06 | 0.386 | 0.127 | MAP kinase 3 inhibitor | 0.127 0.115 DBMET02828 | DBMET02828 | |
| 0.036 | 0.37 | 0.087 | Granulocyte macrophage colony stimulating factor agonist | 0.087 0.057 DBMET02828 0.086 0.061 DBMET02829 | DBMET02828 | |
| 0.03 | 0.364 | 0.126 | Caspase 3 inhibitor | 0.126 0.051 DBMET02829 | DBMET02829 | |
| 0.029 | 0.364 | 0.098 | HIV-1 integrase (Overall Integration) inhibitor | 0.098 0.057 DBMET02829 | DBMET02829 | |
| 0.006 | 0.341 | 0.027 | Liver X receptor beta antagonist | 0.027 0.022 DBMET02829 | DBMET02829 | |
| 0.018 | 0.355 | 0.17 | Expectorant | 0.17 0.028 DBMET02829 | DBMET02829 | |
| 0.02 | 0.359 | 0.066 | Glutamate (mGluR7) antagonist | 0.066 0.051 DBMET02828 0.065 0.052 DBMET02829 | DBMET02828 | |
| 0.018 | 0.359 | 0.037 | Glucagon-like peptide 1 receptor antagonist | 0.037 0.034 DBMET02829 | DBMET02829 | |
| 0.033 | 0.374 | 0.156 | Electrolyte absorption antagonist | 0.105 0.051 DBMET02828 0.156 0.017 DBMET02829 | DBMET02829 | |
| 0.096 | 0.437 | 0.3 | Analgesic | 0.3 0.142 DBMET02829 | DBMET02829 | |
| 0.081 | 0.423 | 0.235 | 5 Hydroxytryptamine release stimulant | 0.235 0.097 DBMET02828 0.182 0.139 DBMET02829 | DBMET02828 | |
| 0.046 | 0.388 | 0.22 | Platelet antagonist | 0.175 0.122 DBMET02829 0.22 0.088 DBMET02827 | DBMET02827 | |
| 0.018 | 0.363 | 0.076 | Prostaglandin F2 alpha antagonist | 0.076 0.026 DBMET02829 | DBMET02829 | |
| 0.005 | 0.352 | 0.023 | Lysophosphatidic acid 1 receptor antagonist | 0.023 0.012 DBMET02829 | DBMET02829 | |
| 0.019 | 0.367 | 0.099 | Glycine receptor antagonist | 0.099 0.034 DBMET02829 | DBMET02829 | |
| 0.003 | 0.352 | 0.029 | Uridine phosphorylase inhibitor | 0.029 0.018 DBMET02829 | DBMET02829 | |
| 0.022 | 0.373 | 0.133 | Myeloperoxidase inhibitor | 0.133 0.015 DBMET02828 | DBMET02828 | |
| 0.008 | 0.362 | 0.048 | Mannosidase inhibitor | 0.041 0.038 DBMET02828 0.048 0.028 DBMET02829 | DBMET02829 | |
| 0.005 | 0.359 | 0.047 | Peroxisome proliferator-activated receptor alpha agonist | 0.047 0.034 DBMET02829 | DBMET02829 | |
| 0.055 | 0.409 | 0.169 | 3C-like protease (Human coronavirus) inhibitor | 0.169 0.075 DBMET02828 0.152 0.098 DBMET02829 | DBMET02828 | |
| 0.008 | 0.362 | 0.067 | Purinergic P2Y14 antagonist | 0.067 0.005 DBMET02829 | DBMET02829 | |
| 0.017 | 0.372 | 0.066 | Phospholipase D inhibitor | 0.066 0.063 DBMET02829 | DBMET02829 | |
| 0.047 | 0.403 | 0.219 | Hexokinase inhibitor | 0.219 0.026 DBMET02829 | DBMET02829 | |
| 0.002 | 0.36 | 0.045 | Nicotinic acid receptor 1 antagonist | 0.045 0.003 DBMET02828 | DBMET02828 | |
| 0.008 | 0.366 | 0.039 | Purinergic P2X3 antagonist | 0.039 0.018 DBMET02826 | DBMET02826 | |
| 0.032 | 0.391 | 0.126 | Amylase inhibitor | 0.126 0.077 DBMET02828 0.108 0.089 DBMET02827 | DBMET02828 | |
| 0.023 | 0.383 | 0.147 | MAP kinase 9 inhibitor | 0.147 0.039 DBMET02828 | DBMET02828 | |
| 0.013 | 0.378 | 0.078 | Protein kinase C beta inhibitor | 0.078 0.032 DBMET02828 | DBMET02828 | |
| 0.005 | 0.371 | 0.044 | Dihydropteroate synthase inhibitor | 0.044 0.022 DBMET02829 | DBMET02829 | |
| 0.004 | 0.372 | 0.037 | HCV NS5B polymerase inhibitor | 0.037 0.016 DBMET02829 | DBMET02829 | |
| 0.006 | 0.375 | 0.047 | Nicotinic acid receptor agonist | 0.032 0.03 DBMET02828 0.047 0.016 DBMET02829 | DBMET02829 | |
| 0.023 | 0.394 | 0.157 | Aminopeptidase B inhibitor | 0.086 0.076 DBMET02828 0.157 0.035 DBMET02829 | DBMET02829 | |
| 0.033 | 0.406 | 0.127 | Adenylate cyclase inhibitor | 0.127 0.061 DBMET02829 | DBMET02829 | |
| 0.057 | 0.431 | 0.127 | Vanilloid 1 agonist | 0.127 0.072 DBMET02829 | DBMET02829 | |
| 0.06 | 0.434 | 0.325 | DNA synthesis inhibitor | 0.223 0.091 DBMET02828 0.325 0.036 DBMET02829 0.234 0.079 DBMET02825 | DBMET02829 | |
| 0.03 | 0.404 | 0.239 | Diuretic | 0.239 0.033 DBMET02829 | DBMET02829 | |
| 0.004 | 0.385 | 0.036 | Nicotinic acid receptor 2 antagonist | 0.036 0.007 DBMET02828 0.035 0.008 DBMET02829 | DBMET02828 | |
| 0.079 | 0.461 | 0.289 | Insulysin inhibitor | 0.224 0.125 DBMET02828 0.289 0.065 DBMET02829 | DBMET02829 | |
| 0.02 | 0.403 | 0.151 | Mucolytic | 0.151 0.032 DBMET02829 | DBMET02829 | |
| 0.036 | 0.419 | 0.163 | ABCA1 expression enhancer | 0.163 0.014 DBMET02829 | DBMET02829 | |
| 0.012 | 0.398 | 0.125 | Anesthetic local | 0.125 0.064 DBMET02829 | DBMET02829 | |
| 0.035 | 0.421 | 0.198 | Insulin sensitizer | 0.198 0.075 DBMET02829 | DBMET02829 | |
| 0.026 | 0.416 | 0.128 | Cytidine deaminase inhibitor | 0.128 0.093 DBMET02829 | DBMET02829 | |
| 0.041 | 0.434 | 0.087 | 3C-Like protease (SARS coronavirus) inhibitor | 0.087 0.051 DBMET02829 | DBMET02829 | |
| 0.016 | 0.411 | 0.106 | GABA aminotransferase inhibitor | 0.091 0.034 DBMET02828 0.106 0.023 DBMET02829 | DBMET02829 | |
| 0.037 | 0.432 | 0.105 | D-Ala-D-Ala ligase inhibitor | 0.087 0.051 DBMET02828 0.105 0.024 DBMET02829 | DBMET02829 | |
| 0.032 | 0.43 | 0.181 | Alpha 2d adrenoreceptor antagonist | 0.181 0.004 DBMET02828 | DBMET02828 | |
| 0.084 | 0.483 | 0.314 | Calcium channel activator | 0.281 0.111 DBMET02828 0.314 0.078 DBMET02829 | DBMET02829 | |
| 0.011 | 0.41 | 0.107 | Phenylalanine 4-hydroxylase inhibitor | 0.067 0.049 DBMET02828 0.107 0.022 DBMET02829 | DBMET02829 | |
| 0.027 | 0.429 | 0.14 | Pyruvate kinase inhibitor | 0.14 0.124 DBMET02829 | DBMET02829 | |
| 0.023 | 0.427 | 0.184 | Keratolytic | 0.184 0.01 DBMET02829 | DBMET02829 | |
| 0.014 | 0.418 | 0.086 | NMDA receptor agonist | 0.086 0.025 DBMET02829 | DBMET02829 | |
| 0.029 | 0.435 | 0.111 | Carbonic anhydrase III inhibitor | 0.111 0.051 DBMET02829 | DBMET02829 | |
| 0.003 | 0.409 | 0.075 | Retinoic acid alpha receptor antagonist | 0.075 0.003 DBMET02829 | DBMET02829 | |
| 0.023 | 0.428 | 0.097 | Potassium channel large-conductance Ca-activated activator | 0.097 0.025 DBMET02828 0.063 0.055 DBMET02829 | DBMET02828 | |
| 0.058 | 0.466 | 0.183 | Histone acetyltransferase inhibitor | 0.165 0.119 DBMET02828 0.183 0.095 DBMET02829 | DBMET02829 | |
| 0.007 | 0.415 | 0.088 | NMDA receptor glycine site agonist | 0.088 0.023 DBMET02829 | DBMET02829 | |
| 0.034 | 0.443 | 0.122 | Photosensitizer | 0.122 0.055 DBMET02829 | DBMET02829 | |
| 0.089 | 0.499 | 0.153 | Heat shock protein 70 antagonist | 0.153 0.039 DBMET02829 | DBMET02829 | |
| 0.008 | 0.421 | 0.091 | Neuraminidase inhibitor | 0.091 0.019 DBMET02829 | DBMET02829 | |
| 0.069 | 0.484 | 0.495 | Histamine release inhibitor | 0.477 0.038 DBMET02828 0.495 0.03 DBMET02829 | DBMET02829 | |
| 0.018 | 0.435 | 0.06 | Factor IXa inhibitor | 0.05 0.038 DBMET02829 0.06 0.027 DBMET02825 0.053 0.033 DBMET02827 | DBMET02825 | |
| 0.028 | 0.447 | 0.198 | Phospholipase A2 inhibitor | 0.198 0.044 DBMET02829 | DBMET02829 | |
| 0.048 | 0.468 | 0.234 | Cyclic AMP phosphodiesterase inhibitor | 0.234 0.072 DBMET02828 0.153 0.148 DBMET02829 | DBMET02828 | |
| 0.007 | 0.428 | 0.04 | Nerve growth factor antagonist | 0.04 0.036 DBMET02829 | DBMET02829 | |
| 0.005 | 0.426 | 0.106 | Retinoic acid receptor agonist | 0.106 0.004 DBMET02829 | DBMET02829 | |
| 0.033 | 0.457 | 0.121 | Carbonic anhydrase XV inhibitor | 0.121 0.046 DBMET02829 | DBMET02829 | |
| 0.041 | 0.466 | 0.203 | Interleukin agonist | 0.203 0.118 DBMET02829 | DBMET02829 | |
| 0.009 | 0.435 | 0.102 | Monophenol monooxygenase inhibitor | 0.102 0.075 DBMET02829 | DBMET02829 | |
| 0.021 | 0.448 | 0.17 | 5 Hydroxytryptamine 3A agonist | 0.17 0.026 DBMET02828 | DBMET02828 | |
| 0.003 | 0.431 | 0.071 | Farnesoid X receptor agonist | 0.071 0.007 DBMET02829 | DBMET02829 | |
| 0.003 | 0.433 | 0.035 | Free fatty acid receptor 1 antagonist | 0.035 0.022 DBMET02829 | DBMET02829 | |
| 0.013 | 0.446 | 0.131 | Protein kinase (CK1) inhibitor | 0.131 0.082 DBMET02828 | DBMET02828 | |
| 0.005 | 0.438 | 0.05 | GABA uptake inhibitor | 0.05 0.015 DBMET02829 | DBMET02829 | |
| 0.03 | 0.465 | 0.226 | Spasmolytic | 0.226 0.102 DBMET02829 | DBMET02829 | |
| 0.006 | 0.445 | 0.076 | Prostaglandin-E synthase inhibitor | 0.076 0.042 DBMET02829 | DBMET02829 | |
| 0.07 | 0.51 | 0.279 | Sodium/bile acid cotransporter inhibitor | 0.279 0.099 DBMET02829 | DBMET02829 | |
| 0.005 | 0.446 | 0.044 | RNA-directed RNA polymerase inhibitor | 0.044 0.016 DBMET02829 | DBMET02829 | |
| 0.005 | 0.446 | 0.099 | Retinoic acid beta receptor agonist | 0.099 0.003 DBMET02829 | DBMET02829 | |
| 0.027 | 0.47 | 0.089 | Bromodomain-containing protein 2 inhibitor | 0.089 0.058 DBMET02828 | DBMET02828 | |
| 0.054 | 0.499 | 0.324 | Antithrombotic | 0.324 0.075 DBMET02829 0.268 0.113 DBMET02825 0.32 0.076 DBMET02827 | DBMET02829 | |
| 0.049 | 0.496 | 0.272 | Transcription factor NF kappa B inhibitor | 0.272 0.112 DBMET02829 0.222 0.149 DBMET02825 0.223 0.148 DBMET02827 | DBMET02829 | |
| 0.014 | 0.461 | 0.055 | Fatty acid synthase inhibitor | 0.055 0.043 DBMET02828 | DBMET02828 | |
| 0.009 | 0.457 | 0.165 | Catalase inhibitor | 0.165 0.023 DBMET02829 | DBMET02829 | |
| 0.005 | 0.455 | 0.039 | Leukocyte elastase inhibitor | 0.039 0.035 DBMET02829 | DBMET02829 | |
| 0.008 | 0.46 | 0.087 | Check point kinase 1 inhibitor | 0.087 0.034 DBMET02828 | DBMET02828 | |
| 0.032 | 0.484 | 0.138 | Cyclooxygenase 3 inhibitor | 0.138 0.059 DBMET02829 | DBMET02829 | |
| 0.058 | 0.511 | 0.284 | Gastrin inhibitor | 0.213 0.13 DBMET02828 0.284 0.045 DBMET02829 | DBMET02829 | |
| 0.022 | 0.475 | 0.171 | Viral attachment inhibitor | 0.171 0.005 DBMET02828 | DBMET02828 | |
| 0.035 | 0.492 | 0.204 | Non-steroidal antiinflammatory agent | 0.204 0.068 DBMET02829 | DBMET02829 | |
| 0.004 | 0.469 | 0.031 | Factor XI inhibitor | 0.031 0.03 DBMET02829 | DBMET02829 | |
| 0.058 | 0.523 | 0.583 | Antibacterial | 0.334 0.111 DBMET02828 0.239 0.188 DBMET02829 0.583 0.022 DBMET02825 0.407 0.074 DBMET02827 | DBMET02825 | |
| 0.061 | 0.528 | 0.143 | Neurotensin receptor agonist | 0.143 0.121 DBMET02828 0.139 0.131 DBMET02829 | DBMET02828 | |
| 0.003 | 0.471 | 0.041 | Kainate receptor antagonist | 0.041 0.028 DBMET02829 | DBMET02829 | |
| 0.018 | 0.487 | 0.057 | CD45 antagonist | 0.057 0.025 DBMET02829 | DBMET02829 | |
| 0.047 | 0.516 | 0.166 | Neurotrophic factor enhancer | 0.166 0.115 DBMET02829 | DBMET02829 | |
| 0.012 | 0.482 | 0.212 | Rho-associated kinase II inhibitor | 0.212 0.01 DBMET02828 | DBMET02828 | |
| 0.015 | 0.487 | 0.118 | Mediator release inhibitor | 0.105 0.064 DBMET02828 0.118 0.05 DBMET02829 | DBMET02829 | |
| 0.024 | 0.5 | 0.102 | Toll-Like receptor 2 antagonist | 0.102 0.101 DBMET02829 | DBMET02829 | |
| 0.005 | 0.485 | 0.046 | Prostaglandin antagonist | 0.046 0.044 DBMET02829 | DBMET02829 | |
| 0.089 | 0.575 | 0.3 | Caspase 9 stimulant | 0.3 0.194 DBMET02828 0.279 0.218 DBMET02829 | DBMET02828 | |
| 0.007 | 0.495 | 0.031 | Glutamate (mGluR4) agonist | 0.031 0.029 DBMET02828 | DBMET02828 | |
| 0.014 | 0.503 | 0.065 | Cathepsin G inhibitor | 0.065 0.06 DBMET02829 | DBMET02829 | |
| 0.027 | 0.517 | 0.086 | Vanilloid agonist | 0.086 0.054 DBMET02829 | DBMET02829 | |
| 0.004 | 0.495 | 0.028 | Leukotriene B4 receptor 2 antagonist | 0.028 0.009 DBMET02829 | DBMET02829 | |
| 0.007 | 0.508 | 0.119 | Retinoic acid alpha receptor agonist | 0.119 0.004 DBMET02829 | DBMET02829 | |
| 0.032 | 0.534 | 0.267 | Nitric oxide antagonist | 0.22 0.061 DBMET02825 0.267 0.047 DBMET02827 | DBMET02827 | |
| 0.019 | 0.528 | 0.131 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.131 0.091 DBMET02828 | DBMET02828 | |
| 0.036 | 0.55 | 0.215 | Transcription factor STAT3 inhibitor | 0.215 0.116 DBMET02829 | DBMET02829 | |
| 0.003 | 0.518 | 0.105 | Methionyl aminopeptidase 2 inhibitor | 0.105 0.004 DBMET02828 | DBMET02828 | |
| 0.006 | 0.527 | 0.141 | Pim-3 kinase inhibitor | 0.141 0.021 DBMET02828 | DBMET02828 | |
| 0.005 | 0.528 | 0.052 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.052 0.049 DBMET02829 | DBMET02829 | |
| 0.004 | 0.53 | 0.052 | Pim-2 kinase inhibitor | 0.052 0.043 DBMET02828 | DBMET02828 | |
| 0.005 | 0.531 | 0.033 | Peroxisome proliferator-activated receptor delta antagonist | 0.033 0.023 DBMET02829 | DBMET02829 | |
| 0.033 | 0.564 | 0.155 | Focal adhesion kinase 2 inhibitor | 0.155 0.122 DBMET02828 | DBMET02828 | |
| 0.01 | 0.548 | 0.266 | MAP kinase 8 inhibitor | 0.266 0.009 DBMET02828 | DBMET02828 | |
| 0.025 | 0.563 | 0.086 | MAP kinase kinase 8 inhibitor | 0.086 0.03 DBMET02828 | DBMET02828 | |
| 0.027 | 0.572 | 0.189 | 12-Lipoxygenase inhibitor | 0.189 0.163 DBMET02829 | DBMET02829 | |
| 0.006 | 0.562 | 0.072 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.072 0.058 DBMET02828 | DBMET02828 | |
| 0.004 | 0.562 | 0.048 | Thymidylate synthase inhibitor | 0.048 0.03 DBMET02828 | DBMET02828 | |
| 0.007 | 0.569 | 0.061 | Maillard reaction inhibitor | 0.061 0.034 DBMET02829 | DBMET02829 | |
| 0.021 | 0.584 | 0.161 | DNA methyltransferase I inhibitor | 0.161 0.094 DBMET02829 | DBMET02829 | |
| 0.011 | 0.58 | 0.174 | Lck kinase inhibitor | 0.174 0.052 DBMET02828 | DBMET02828 | |
| 0.003 | 0.573 | 0.048 | TRPM8 blocker | 0.048 0.017 DBMET02829 | DBMET02829 | |
| 0.012 | 0.587 | 0.09 | Estrogen receptor beta antagonist | 0.09 0.084 DBMET02829 | DBMET02829 | |
| 0.035 | 0.617 | 0.2 | Transcription factor STAT inhibitor | 0.2 0.138 DBMET02829 | DBMET02829 | |
| 0.006 | 0.596 | 0.1 | Plasminogen activator inhibitor antagonist | 0.1 0.01 DBMET02829 | DBMET02829 | |
| 0.008 | 0.605 | 0.052 | Sphingosine 1-phosphate receptor 5 agonist | 0.052 0.041 DBMET02829 | DBMET02829 | |
| 0.007 | 0.604 | 0.138 | Protein kinase B gamma inhibitor | 0.138 0.019 DBMET02828 | DBMET02828 | |
| 0.008 | 0.612 | 0.071 | CDC25A inhibitor | 0.071 0.055 DBMET02829 | DBMET02829 | |
| 0.01 | 0.617 | 0.053 | Heparanase inhibitor | 0.053 0.038 DBMET02829 | DBMET02829 | |
| 0.034 | 0.668 | 0.171 | NOS3 expression enhancer | 0.166 0.059 DBMET02829 0.128 0.101 DBMET02825 0.171 0.056 DBMET02827 | DBMET02827 | |
| 0.005 | 0.641 | 0.096 | Rho-associated kinase inhibitor | 0.096 0.036 DBMET02828 | DBMET02828 | |
| 0.017 | 0.662 | 0.215 | Vasodilator | 0.215 0.093 DBMET02829 0.18 0.122 DBMET02825 0.207 0.099 DBMET02827 | DBMET02829 | |
| 0.008 | 0.669 | 0.184 | Polo-like kinase-4 inhibitor | 0.184 0.02 DBMET02828 | DBMET02828 | |
| 0.025 | 0.697 | 0.146 | Interleukin 4 antagonist | 0.146 0.053 DBMET02829 | DBMET02829 | |
| 0.004 | 0.678 | 0.094 | Prostaglandin EP2 antagonist | 0.094 0.02 DBMET02829 | DBMET02829 | |
| 0.034 | 0.709 | 0.569 | Cyclophilin D inhibitor | 0.277 0.184 DBMET02825 0.569 0.033 DBMET02827 | DBMET02827 | |
| 0.007 | 0.714 | 0.148 | M17 leucyl aminopeptidase inhibitor | 0.148 0.057 DBMET02829 | DBMET02829 | |
| 0.002 | 0.712 | 0.04 | Methionyl aminopeptidase 1 inhibitor | 0.04 0.012 DBMET02828 | DBMET02828 | |
| 0.018 | 0.757 | 0.087 | Interleukin 5 antagonist | 0.087 0.059 DBMET02829 | DBMET02829 | |
| 0.023 | 0.774 | 0.269 | Immunomodulator | 0.269 0.101 DBMET02827 | DBMET02827 | |
| 0.004 | 0.759 | 0.063 | HIV-1 integrase (3'-Processing) inhibitor | 0.063 0.044 DBMET02829 | DBMET02829 | |
| 0.02 | 0.778 | 0.177 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.177 0.035 DBMET02829 | DBMET02829 | |
| 0 | 0.775 | 0.011 | Mannitol 2-dehydrogenase inhibitor | 0.011 0.004 DBMET02829 | DBMET02829 | |
| 0.035 | 0.817 | 0.253 | Lipocortins synthesis antagonist | 0.253 0.032 DBMET02829 | DBMET02829 | |
| 0.005 | 0.791 | 0.149 | Mcl-1 antagonist | 0.149 0.091 DBMET02829 | DBMET02829 | |
| 0.009 | 0.816 | 0.039 | Glutamate (mGluR8) antagonist | 0.039 0.018 DBMET02829 | DBMET02829 | |
| 0.005 | 0.818 | 0.168 | Hypolipemic | 0.168 0.12 DBMET02829 0.156 0.13 DBMET02827 | DBMET02829 | |
| 0.015 | 0.829 | 0.143 | Toll-Like receptor 4 antagonist | 0.094 0.08 DBMET02825 0.143 0.025 DBMET02827 | DBMET02827 | |
| 0.005 | 0.838 | 0.108 | Lipid peroxidase inhibitor | 0.108 0.107 DBMET02825 | DBMET02825 | |
| 0.015 | 0.849 | 0.101 | DNA polymerase I inhibitor | 0.101 0.085 DBMET02827 | DBMET02827 | |
| 0.005 | 0.856 | 0.586 | Topoisomerase I inhibitor | 0.586 0.003 DBMET02825 0.085 0.084 DBMET02827 | DBMET02825 | |
| 0.003 | 0.856 | 0.06 | Nicotinic acid receptor 2 agonist | 0.06 0.011 DBMET02829 | DBMET02829 | |
| 0.007 | 0.863 | 0.161 | Thrombolytic | 0.161 0.073 DBMET02825 0.139 0.09 DBMET02827 | DBMET02825 | |
| 0.01 | 0.887 | 0.146 | CDK3/cyclin E inhibitor | 0.146 0.03 DBMET02828 | DBMET02828 | |
| 0.005 | 0.888 | 0.33 | Antioxidant | 0.33 0.052 DBMET02825 0.326 0.053 DBMET02827 | DBMET02825 | |
| 0.01 | 0.893 | 0.445 | Apoptosis agonist | 0.445 0.093 DBMET02825 0.309 0.166 DBMET02827 | DBMET02825 | |
| 0.004 | 0.888 | 0.058 | Neuraminidase (Influenza A) inhibitor | 0.058 0.014 DBMET02829 | DBMET02829 | |
| 0.004 | 0.89 | 0.13 | Protein-tyrosine phosphatase 1B inhibitor | 0.13 0.056 DBMET02829 | DBMET02829 | |
| 0.003 | 0.889 | 0.059 | Cyclin E inhibitor | 0.059 0.041 DBMET02828 | DBMET02828 | |
| 0.004 | 0.895 | 0.287 | Pim-1 kinase inhibitor | 0.287 0.006 DBMET02828 | DBMET02828 | |
| 0.009 | 0.901 | 0.329 | Hypoglycemic | 0.274 0.063 DBMET02825 0.329 0.043 DBMET02827 | DBMET02827 | |
| 0.004 | 0.9 | 0.15 | CDK2/cyclin E2 inhibitor | 0.15 0.017 DBMET02828 | DBMET02828 | |
| 0.008 | 0.914 | 0.058 | Factor III inhibitor | 0.058 0.02 DBMET02829 | DBMET02829 | |
| 0.006 | 0.914 | 0.842 | Autotaxin inhibitor | 0.842 0.002 DBMET02828 | DBMET02828 | |
| 0.003 | 0.945 | 0.281 | Selectin antagonist | 0.176 0.014 DBMET02825 0.281 0.006 DBMET02827 | DBMET02827 | |
| 0.004 | 0.948 | 0.29 | Free radical scavenger | 0.29 0.054 DBMET02825 0.267 0.062 DBMET02827 | DBMET02825 | |
| 0.007 | 0.952 | 0.191 | Platelet adhesion inhibitor | 0.191 0.076 DBMET02827 | DBMET02827 | |
| 0.01 | 0.957 | 0.286 | Hepatoprotectant | 0.271 0.038 DBMET02825 0.286 0.034 DBMET02827 | DBMET02827 | |
| 0.014 | 0.964 | 0.087 | Transcription factor NF kappa B stimulant | 0.078 0.075 DBMET02825 0.087 0.056 DBMET02827 | DBMET02827 | |
| 0.004 | 0.961 | 0.178 | Protein-tyrosine phosphatase inhibitor | 0.178 0.057 DBMET02829 | DBMET02829 | |
| 0.004 | 0.965 | 0.051 | Antibiotic Aminoglycoside-like | 0.05 0.013 DBMET02825 0.051 0.012 DBMET02827 | DBMET02827 | |
| 0.002 | 0.969 | 0.041 | NMDA 2D receptor antagonist | 0.041 0.01 DBMET02829 | DBMET02829 | |
| 0.028 | 0.995 | 0.287 | Peptidyltransferase inhibitor | 0.286 0.03 DBMET02825 0.287 0.03 DBMET02827 | DBMET02827 | |
| 0.005 | 0.973 | 0.467 | Angiogenesis stimulant | 0.396 0.022 DBMET02825 0.467 0.014 DBMET02827 | DBMET02827 | |
| 0.019 | 0.994 | 0.402 | Interleukin 2 agonist | 0.307 0.069 DBMET02825 0.402 0.027 DBMET02827 | DBMET02827 | |
| 0.003 | 0.982 | 0.063 | Protein 50S ribosomal subunit inhibitor | 0.054 0.035 DBMET02825 0.063 0.029 DBMET02827 | DBMET02827 | |
| 0.005 | 0.989 | 0.242 | Apoptosis antagonist | 0.205 0.172 DBMET02825 0.242 0.136 DBMET02827 | DBMET02827 | |
| 0.003 | 0.992 | 0.026 | Toll-Like receptor 4 agonist | 0.026 0.019 DBMET02827 | DBMET02827 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |